IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$106.85 MLiabilities$179.49 MNon-current liabilities$72.64 MEquity$736.05 MGross equity(calculated)$3.64 BCurrent assets$464.26 MAssets$915.53 MNon-current assets$451.27 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSShort-term investmentsCash and cash equivalentsTrade accounts receivableInventoryPrepaid expenses and other assetsIntangible assets, netProperty and equipment, netOperating lease right-of-use assetsLong-term assetsRestricted cashAccrued expenses and other liabilitiesAccounts payableOperating lease liabilitiesOperating lease liabilities - non-currentDeferred tax liabilitiesAdditional paid-in capitalAccumulated other comprehensive incomeCommon stock, $0.000041666 par value; 650,000,000 shares authorized, 452,971,016 and 411,938,061 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyPreferred stock, Value - Series B Convertible Preferred StockCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitCurrent liabilitiesCurrent liabilities$106.85 MAccrued expenses and other liabilitiesAccrued expenses and other liabilities$77.96 MLiabilitiesLiabilities$179.49 MAccounts payableAccounts payable$26.21 MOperating lease liabilitiesOperating lease liabilities$2.67 MNon-current liabilitiesNon-current liabilities$72.64 MOperating lease liabilities - non-currentOperating lease liabilities - non-current$43.33 MEquityEquity$736.05 MDeferred tax liabilitiesDeferred tax liabilities$29.31 MGross equity (calculated)Gross equity(calculated)$3.64 BCurrent assetsCurrent assets$464.26 MShort-term investmentsShort-term investments$186.91 MAssetsAssets$915.53 MCash and cash equivalentsCash and cash equivalents$110.77 MTrade accounts receivableTrade accounts receivable$102.12 MInventoryInventory$55.59 MPrepaid expenses and other assetsPrepaid expenses and other assets$8.87 MNon-current assetsNon-current assets$451.27 MIntangible assets, netIntangible assets, net$263.89 MAdditional paid-in capitalAdditional paid-in capital$3.62 BProperty and equipment, netProperty and equipment, net$131.46 MOperating lease right-of-use assetsOperating lease right-of-use assets$43.48 MLong-term assetsLong-term assets$6.43 MRestricted cashRestricted cash$6.01 MAccumulated other comprehensive incomeAccumulated other comprehensive income$13.08 MCommon stock, $0.000041666 par value; 650,000,000 shares authorized, 452,971,016 and 411,938,061 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$19.00 KPreferred stock, Value - Series B Convertible Preferred StockPreferred stock, Value - SeriesB Convertible Preferred Stock$2.00 KAccumulated deficitAccumulated deficit−$2.90 B
Chart details

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
915,531,000 US dollars
Current assets
464,257,000 US dollars
Non-current assets
451,274,000 US dollars
Liabilities
179,486,000 US dollars
Current liabilities
106,848,000 US dollars
Non-current liabilities
72,638,000 US dollars
Equity
736,045,000 US dollars
Short-term investments
186,906,000 US dollars
Cash and cash equivalents
110,768,000 US dollars
Trade accounts receivable
102,119,000 US dollars
Inventory
55,590,000 US dollars
Prepaid expenses and other assets
8,874,000 US dollars
Intangible assets, net
263,894,000 US dollars
Property and equipment, net
131,464,000 US dollars
Operating lease right-of-use assets
43,480,000 US dollars
Long-term assets
6,431,000 US dollars
Restricted cash
6,005,000 US dollars
Accrued expenses and other liabilities
77,964,000 US dollars
Accounts payable
26,211,000 US dollars
Operating lease liabilities
2,673,000 US dollars
Operating lease liabilities - non-current
43,330,000 US dollars
Deferred tax liabilities
29,308,000 US dollars
Additional paid-in capital
3,624,836,000 US dollars
Accumulated other comprehensive income
13,078,000 US dollars
Common stock, $0.000041666 par value; 650,000,000 shares authorized, 452,971,016 and 411,938,061 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
19,000 US dollars
Preferred stock, Value - Series B Convertible Preferred Stock
2,000 US dollars
Accumulated deficit
negative 2,901,890,000 US dollars
Gross equity (calculated)
3,637,935,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!